Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
An Open, Escalating Phase I Clinical Trial of BAT8003 (for Injection) on the Safety, Tolerability and Pharmacokinetics for Patients With Advanced Epithelial Cancer
Sponsor: Bio-Thera Solutions
Terminated
Considering that the safety risk will affect the subsequent development, it is decided to terminate the test voluntarily
This PHASE1 trial investigates Advanced Solid Cancer and is currently terminated or withdrawn. Bio-Thera Solutions leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Oct 2021 — Jun 2023 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Apr 2019 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bio-Thera Solutions
For direct contact, visit the study record on ClinicalTrials.gov .